October 26, 2017

Novocure Reports Third Quarter 2017 Financial Results and Provides Company Update

Third quarter 2017 net revenues of $50.1 million, reflecting 131 percent growth versus third quarter 2016 and 31 percent growth versus second quarter 2017 1,683 active patients at September 30, 2017, an increase of 71 percent from September 30, 2016, and 15 percent… Read More
learn more
October 16, 2017

Novocure Announces Data Presentations at the IASLC 18th World Conference on Lung Cancer

The conference is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today five data presentations at the International Associations for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer, October 15 to… Read More
learn more
October 2, 2017

Novocure to Report Third Quarter 2017 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2017 on Thursday, October 26, 2017, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and… Read More
learn more
September 24, 2017

Combination of Optune® with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Diagnosed Glioblastoma Patients

Newly diagnosed glioblastoma patients treated with Optune plus temozolomide were able to maintain quality of life for longer compared to those treated with temozolomide alone Data presented today as a late-breaking oral presentation at the American Society for Radiation Oncology’s 2017 Annual Meeting ST. HELIER,… Read More
learn more
September 22, 2017

Novocure Announces Data Presentations at the American Society for Radiation Oncology’s 2017 Annual Meeting

Late-breaking oral presentation to focus on Optune five-year survival and health-related quality of life data ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today four presentations on Tumor Treating Fields (TTFields) at the American Society for Radiation Oncology’s (ASTRO) 2017 Annual Meeting, September 24 through September… Read More
learn more
September 6, 2017

Novocure Announces Data Presentations at the ESMO 2017 Congress

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that four data presentations on Tumor Treating Fields (TTFields) will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress, September 8 through September 12 in Madrid, Spain. Among the highlights is a poster discussion of the overall… Read More
learn more
September 5, 2017

German Federal Joint Committee Announces Decision to Support a Clinical Trial to Study Optune® for the Treatment of Newly Diagnosed Glioblastoma

Proposed trial design will examine the benefit of combining Optune with radiation therapy and temozolomide prior to the initiation of maintenance temozolomide ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that the German Federal Joint Committee, (Gemeinsamer Bundesausschuss or G-BA), has published its decision to support… Read More
learn more
August 24, 2017

Novocure to Present at Two Upcoming Investor Conferences in September

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences in September. William Doyle, Novocure’s Executive Chairman, will participate in the Wells Fargo 2017 Healthcare Conference on September 6, 2017, in Boston. Mr. Doyle’s presentation will begin at 10:15 a.m. Read More
learn more
August 8, 2017

Novocure™ Announces National Reimbursement for Optune® in Austria

The decision marks Novocure’s first national coverage policy ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today it has signed a contract with the Federation of the Austrian Social Insurance Institutions which grants reimbursement across Austria for Optune – Novocure’s Tumor Treating Fields (TTFields) delivery system –… Read More
learn more
August 2, 2017

Novocure to Present at the 2017 Wedbush PacGrow Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in the 2017 Wedbush PacGrow Healthcare Conference on August 15, 2017, in New York City. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Mr. Doyle’s presentation… Read More
learn more